Q&A

Exclusive interviews with industry leaders


  • story image
    Image attribution tooltip
    Stock via Getty Images

    How the CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing

    Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.

    Meagan Parrish • July 7, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

    As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

    Kim Ribbink • June 30, 2022
  • story image
    Image attribution tooltip
    Permission granted by University of Pennsylvania

    The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman

    The two Penn Medicine researchers whose work brought the mRNA vaccines into COVID-19 fruition want to see the pharma world embrace early science.

    Michael Gibney • June 29, 2022
  • story image
    Image attribution tooltip

    Permission granted by Dan Vahdat.

    'Nobel Prize of pharma' helps put Huma's digital health platform on the global map

    The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.

    Kim Ribbink • June 23, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Biotech spotlight: Karuna Therapeutics' mission to rejuvenate the field of neuroscience

    An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

    Kim Ribbink • June 16, 2022
  • story image
    Image attribution tooltip
    iStock via Getty Images

    Why biomanufacturing is the next innovation frontier for genomic therapies

    While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.

    Meagan Parrish • June 13, 2022
  • story image
    Image attribution tooltip
    Permission granted by Editas/Gilmore O'Neill

    First 90 Days: Editas Medicine's Gilmore O'Neill

    The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.

    Michael Gibney • June 13, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    A combo of precision meds and diagnostics could disrupt mental healthcare

    HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.

    Kelly Bilodeau • June 8, 2022
  • story image
    Image attribution tooltip

    Permission granted by David Jimenez.

    First 90 Days: Janssen Immunology's David Jimenez

    The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.

    Taren Grom • June 6, 2022
  • story image
    Image attribution tooltip
    Permission granted by Sosei Heptares/Chris Cargill

    First 90 Days: Sosei Heptares' Chris Cargill

    The company’s new CEO is looking to drive growth through collaboration and transparency.

    Kim Ribbink • May 31, 2022
  • story image
    Image attribution tooltip

    Permission granted by Michelle Keefe. 

    First 90 Days: Syneos Health's Michelle Keefe

    The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.

    Taren Grom • May 23, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    The UK-based company that's striving to overcome the limitations of T cell receptor innovation

    Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.

    Kim Ribbink • May 23, 2022
  • story image
    Image attribution tooltip
    iStock via Getty Images

    Ironwood Pharmaceuticals is charting a course to become a giant in GI

    Ironwood’s CEO, Tom McCourt, discusses the company’s strategy for leveling up in the GI market. 

    Karissa Waddick • May 19, 2022
  • story image
    Image attribution tooltip
    Spencer Platt via Getty Images

    BriOri BioTech sets the stage for the comeback of Vioxx

    With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.

    Kelly Bilodeau • May 17, 2022
  • story image
    Image attribution tooltip
    Natali_Mis via Getty Images

    Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

    Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

    Michael Gibney • May 17, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

    With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

    Taren Grom • May 9, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    One company's failed drug is this company's 'jewel'

    Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

    Meagan Parrish • May 2, 2022
  • story image
    Image attribution tooltip

    Permission granted by Alan Millar. 

    How an open platform can shake up the drug development process

    TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.

    Kim Ribbink • April 28, 2022
  • story image
    Image attribution tooltip
    iStock via Getty Images

    Real-world data is making drug development more true to life

    How RWD is moving from the background to the spotlight in pharma’s development process.

    Kelly Bilodeau • April 26, 2022
  • story image
    Image attribution tooltip
    iStock via Getty Images

    How OliX Pharmaceuticals is riding the RNAi wave

    While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

    Karissa Waddick and Taren Grom • April 25, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    The cannabis vanguard: A rare disease company looks to pioneer in the space

    Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.

    Jared Whitlock • April 21, 2022
  • story image
    Image attribution tooltip
    iStock via Getty Images

    A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'

    Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.

    Alexandra Pecci • April 21, 2022
  • story image
    Image attribution tooltip
    Justin Sullivan / Staff via Getty Images

    How pharma can up its social media game

    Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities. 

    Karissa Waddick • April 18, 2022
  • story image
    Image attribution tooltip
    Yongyuan via Getty Images

    Biotech goes Hollywood

    A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

    Taren Grom • April 13, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Down but not out: How AVEO's CEO steered the company past an FDA rejection

    Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.

    Kim Ribbink • April 5, 2022